Niagen Bioscience (NAGE) Fireside chat summary
Event summary combining transcript, slides, and related documents.
Fireside chat summary
15 Jul, 2026Introduction and agenda
Discussion focused on the strategic expansion into pharmaceutical development, particularly the NB4168 drug program targeting accelerated aging and rare genetic diseases.
Audience Q&A was included, with questions submitted live and in advance.
Background and experience of the speaker
The team includes leading NAD researchers, such as Vil Bohr and Dr. Charles Brenner, with extensive experience in orphan diseases and anti-aging research.
Additional world-class scientific advisors are being added to strengthen expertise.
Current industry trends
Growing awareness and demand for NAD-related products, with steady growth in core supplement and ingredient businesses.
Expansion into telehealth and topical NAD products, alongside pharmaceutical development.
Latest events from Niagen Bioscience
- A profitable NAD+ platform is funding expansion into IVs, skincare, and therapeutics.NAGE
Corporate presentation - Q3 sales fell 20% as investment and new launches targeted future growth.NAGEQ3 2026
- Rare-disease drug ambitions extend a profitable NAD platform into new channels.NAGELD Micro 20th Annual Main Event Conference
- Strong growth, innovation, and a leading NAD drug pipeline position the company for future success.NAGE17th Annual Midwest IDEAS Conference
- Strong NAD+ supplement sales, new skincare launches, and robust cash flow support biotech growth.NAGECanaccord Genuity's 46th Annual Growth Conference
- Q2 2026 delivered $29.8M sales, $1M net income, and major telehealth and pharma launches.NAGEQ2 2026
- Advancing NB4168 for rare genetic diseases with strong clinical data and premium market potential.NAGECorporate presentation
- Patented NAD+ products, strong clinical data, and expanding verticals drive robust growth.NAGECorporate presentation
- Record revenue, profitability, and cash flow set the stage for double-digit growth in 2025.NAGEQ4 2024